594,349 Ionis Pharmaceuticals, Inc. $IONS Shares Acquired by GW&K Investment Management LLC

GW&K Investment Management LLC raised its stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by 79.6% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,341,315 shares of the company’s stock after buying an additional 594,349 shares during the period. GW&K Investment Management LLC owned 0.81% of Ionis Pharmaceuticals worth $59,890,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Landscape Capital Management L.L.C. acquired a new position in shares of Ionis Pharmaceuticals during the third quarter worth $644,000. Public Sector Pension Investment Board bought a new position in shares of Ionis Pharmaceuticals in the 3rd quarter valued at $4,276,000. Edgestream Partners L.P. bought a new position in shares of Ionis Pharmaceuticals in the 3rd quarter valued at $807,000. Ground Swell Capital LLC acquired a new stake in shares of Ionis Pharmaceuticals during the 3rd quarter valued at $547,000. Finally, Allworth Financial LP boosted its holdings in shares of Ionis Pharmaceuticals by 79.8% during the 3rd quarter. Allworth Financial LP now owns 928 shares of the company’s stock valued at $41,000 after acquiring an additional 412 shares in the last quarter. Institutional investors and hedge funds own 93.86% of the company’s stock.

Key Ionis Pharmaceuticals News

Investors following IONS have been watching these news items:

  • Positive Sentiment: The European Union approved Tryngolza for severe hypertriglyceridemia, expanding its reach and making it the first RNA-targeted therapy approved for this patient population in the EU. Article: Ionis’ Tryngolza Gets EU Approval for Severe Hypertriglyceridemia
  • Neutral Sentiment: HC Wainwright maintained its Buy rating and $70 target, despite lowering its earnings forecasts for multiple quarters and for fiscal 2026 and 2027.
  • Negative Sentiment: Guggenheim lowered its price target to $65 from $80, although it kept a Buy rating. The reduced target, alongside HC Wainwright’s lower earnings estimates—including a cut to its FY2027 forecast from a $1.25 loss per share to a $1.94 loss—may weigh on sentiment. Article: Ionis Pharmaceuticals Stock Price Target Cut by Guggenheim

Insider Buying and Selling

In other news, EVP Shannon L. Devers sold 1,357 shares of the stock in a transaction on Friday, October 16th. The shares were sold at an average price of $43.54, for a total transaction of $59,083.78. Following the completion of the sale, the executive vice president directly owned 17,811 shares in the company, valued at $775,490.94. This represents a 7.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Michael R. Hayden bought 5,000 shares of the stock in a transaction that occurred on Tuesday, November 10th. The shares were purchased at an average cost of $29.64 per share, with a total value of $148,200.00. Following the purchase, the director directly owned 27,000 shares of the company’s stock, valued at $800,280. The trade was a 22.73% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. 1.81% of the stock is currently owned by insiders.

Ionis Pharmaceuticals Trading Down 0.7%

Shares of IONS stock opened at $27.21 on Friday. The stock has a market cap of $4.53 billion, a price-to-earnings ratio of -8.20 and a beta of 0.43. The stock has a 50-day moving average of $41.31 and a 200-day moving average of $63.46. The company has a current ratio of 5.43, a quick ratio of 5.36 and a debt-to-equity ratio of 3.42. Ionis Pharmaceuticals, Inc. has a 1-year low of $26.55 and a 1-year high of $86.74.

Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) last issued its quarterly earnings data on Monday, November 9th. The company reported ($0.66) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.23) by $0.57. The company had revenue of $242.72 million during the quarter, compared to the consensus estimate of $178.17 million. Ionis Pharmaceuticals had a negative return on equity of 120.62% and a negative net margin of 56.98%. The firm’s revenue was up 54.8% compared to the same quarter last year. During the same period last year, the company earned ($0.80) earnings per share. On average, equities research analysts forecast that Ionis Pharmaceuticals, Inc. will post -3.57 earnings per share for the current year.

Wall Street Analysts Forecast Growth

IONS has been the topic of a number of recent research reports. Wells Fargo & Company cut their price target on Ionis Pharmaceuticals from $95.00 to $80.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 10th. Royal Bank Of Canada dropped their price objective on shares of Ionis Pharmaceuticals from $85.00 to $60.00 and set an “outperform” rating for the company in a report on Tuesday, November 10th. Morgan Stanley dropped their price objective on shares of Ionis Pharmaceuticals from $104.00 to $75.00 and set an “overweight” rating for the company in a report on Tuesday, November 10th. Barclays cut their target price on shares of Ionis Pharmaceuticals from $90.00 to $85.00 and set an “overweight” rating on the stock in a research report on Wednesday, September 9th. Finally, Wall Street Zen raised shares of Ionis Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, November 14th. Nineteen analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $75.00.

View Our Latest Stock Report on IONS

Ionis Pharmaceuticals Profile

(Free Report)

Ionis Pharmaceuticals is a biotechnology company that discovers and develops RNA-targeted medicines, with a focus on antisense oligonucleotides. Its medicines are designed to act on RNA and change the production of proteins linked to disease. The company’s research and development programs span neurological, cardiovascular, metabolic and rare diseases. Ionis has developed medicines that it commercializes itself and products advanced or marketed with pharmaceutical partners. Its medicines and partnered products include treatments for conditions such as spinal muscular atrophy and transthyretin amyloidosis.

Further Reading

Want to see what other hedge funds are holding IONS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report).

Institutional Ownership by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.